Differences in platelet activation by prolactin and leptin.
Hormones such as prolactin and leptin have recently been recognized as potent platelet aggregation co-activators, and have therefore been postulated as an additional risk factor for both arterial and venous thrombosis. Clinical situations exist that are known to be associated with higher leptin and/or prolactin levels (obesity, pregnancy, prolactinomas and anti-psychotic therapy respectively) and increased venous thrombosis or atherosclerosis risk. Therefore, we compared the impact of both hormones on platelet activation in vitro and in vivo. First, we investigated platelet aggregation and P-selectin expression after stimulation with 1,000 mU/l prolactin or 100 ng/ml leptin in five healthy volunteers in vitro. Prolactin revealed significant higher levels of P-selectin expression and platelet aggregation than leptin in all subjects. We also compared the correlation of prolactin and leptin values with the P-selection expression on platelets. Previously, we detected a significant correlation between prolactin values and ADP-stimulated P-selectin expression on platelets in pregnant women, patients with pituitary tumours, and patients on anti-psychotic therapy. In contrast, leptin did not correlate with P-selectin expression in all subject groups investigated. However, leptin correlated with body mass index in the subjects investigated. Our data indicate that prolactin has a stronger effect on platelet activation as leptin in vitro and in vivo. Moreover, our data suggest that the stronger effect of prolactin on ADP-stimulated platelet aggregation, compared to leptin, depends on higher stimulation of CD62p expression by prolactin.
Wallaschofski
H
H
Department of Internal Medicine I, University of Erlangen, Ulmenweg 18, 91054 Erlangen, Germany. Henri.Wallaschofski@med1.imed.uni-erlangen.de
Kobsar
A
A
Sokolova
O
O
Siegemund
A
A
Stepan
H
H
Faber
R
R
Eigenthaler
M
M
Lohmann
T
T
D014150:Antipsychotic Agents / Q000494:pharmacology; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000097:blood* / Q000209:etiology; D020738:Leptin / Q000502:physiology*; D019007:P-Selectin / Q000378:metabolism; D010911:Pituitary Neoplasms / Q000097:blood* / Q000150:complications; D015539:Platelet Activation / Q000502:physiology*; D010974:Platelet Aggregation / Q000187:drug effects / Q000502:physiology; D011247:Pregnancy / Q000097:blood; D011388:Prolactin / Q000502:physiology*; D015175:Prolactinoma / Q000097:blood* / Q000150:complications; D012016:Reference Values; D018709:Statistics, Nonparametric
D014150:Antipsychotic Agents; D020738:Leptin; D019007:P-Selectin; D011388:Prolactin